公开(公告)号：WO2016172124A1

公开(公告)日：2016-10-27

申请号：PCT/US2016/028316

申请日：2016-04-19

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  GROSSMAN, Iris ,  HAYDEN, Michael ,  ROSS, Colin, James Douglas ,  LAIFENFELD, Daphna ,  DAVIS, Matthew

Inventor： GROSSMAN, Iris ,  HAYDEN, Michael ,  ROSS, Colin, James Douglas ,  LAIFENFELD, Daphna ,  DAVIS, Matthew

IPC: A61K38/02 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K9/0019 ,  A61K38/02 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent, with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

Abstract translation: 本发明提供了一种用多种硬化症或单一临床攻击治疗患有多发性硬化的人类受试者的方法，所述多发性硬化症包括含有醋酸格拉默和药学上可接受的载体的药物组合物，包括以下步骤：（i）确定 对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的对象：rs1894408，kgp7747883，kgp6599438，rs10162089，rs16886004，kgp8110667，kgp8817856，kgp24415534，kgp6214351和rs759458，（ii）鉴定 该受试者作为乙酸格拉默的预测应答者，如果受试者的基因型在kgp8110667，rs10162089，rs759458和kgp6214351的位置包含一个或多个A等位基因，或位于kgp24415534，kgp6599438，kgp7747883，kgp8817856的一个或多个G等位基因 ，rs16886004和rs1894408; 以及iii）仅当所述受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

公开(公告)号：WO2015061367A1

公开(公告)日：2015-04-30

申请号：PCT/US2014/061647

申请日：2014-10-21

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  TCHELET, Amir ,  HAYDEN, Michael ,  HAYARDENY, Liat ,  ROSS, Colin, James Douglas ,  GROSSMAN, Iris ,  LADKANI, David

Inventor： TCHELET, Amir ,  HAYDEN, Michael ,  HAYARDENY, Liat ,  ROSS, Colin, James Douglas ,  GROSSMAN, Iris ,  LADKANI, David

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K38/02 ,  A61K38/16 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype corresponding to the nucleotide polymorphisms consisting of: Group 1, of the subject at a location location of one or more single (SNPs) selected from the group.

Abstract translation: 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：（i）确定对应于 所述核苷酸多态性由选自组中的一个或多个单个（SNP）的位置位置处的受试者的组1组成。